.png){kind=icon}
.png){kind=icon}
Return
Co-encapsulation of Temozolomide and PbS Quantum Dots in Apoferritin for Transferrin Receptor 1 Targeting; Imaging and Treatment of Glioblastoma
.png){kind=icon}
OA
AI
DOI：10.1039/D5NA00557D.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Apoferritin (AFt) nanocages represent a promising drug delivery platform by targeting transferrin receptor 1 (TfR1) abundantly expressed on both blood brain barrier (BBB) endothelial and glioma cells offering promising opportunities for intractable brain cancer treatment. We report the development of a theranostic agent based on lead sulfide quantum dots (PbS QDs) and temozolomide (TMZ) co-encapsulated inside horse spleen AFt cages (AFt-PbS-TMZ). In vitro evaluation of AFt-PbS-TMZ revealed cancer-selective enhancement of growth inhibition in glioblastoma (GBM) cells (U373M; U373V; and U87MG) compared to non-encapsulated agents. These findings in two-dimensional cultures were further corroborated by the results in three-dimensional 3D U87MG tumour spheroids; where the use of AFt-PbS-TMZ significantly enhanced the TMZ efficacy; the treatment resulted in a significant (p<0.0001) decrease in spheroid volumes and cell viability. Additionally; the near-infrared emission of the PbS QDs enabled imaging of the nanoparticle delivery. The emission of the PbS QDs was clearly detectable within the cell spheroids; even at concentrations significantly lower than GI50 values; offering opportunities for non-invasive deep tissue imaging. These results reveal that AFt-PbS-TMZ can be an efficient theranostic agent for targeted cancer drug delivery; addressing limitations associated with current treatment and therapeutic monitoring.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.6
Papers:
853
Citations:
1.5W
Organization
No organization information available